MK-2140 (zilovertamab vedotin) for B-Cell Lymphoma

James Lind Centro de Investigación del Cáncer ( Site 2705), Temuco, Chile
B-Cell LymphomaMK-2140 (zilovertamab vedotin) - Biological
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial will test how well a new cancer drug called zilovertamab vedotin works and how safe it is.

Eligible Conditions
  • Diffuse Large B Cell Lymphoma (DLBCL)

Treatment Effectiveness

Phase-Based Effectiveness

1 of 3
Phase 2

Study Objectives

1 Primary · 3 Secondary · Reporting Duration: Up to approximately 50 months

Month 50
Duration of Response (DOR) per Lugano Response Criteria
Number of Participants Who Discontinue Study Treatment Due to an AE
Number of Participants Who Experience an Adverse Event (AE)
Objective Response Rate (ORR) per Lugano Response Criteria

Trial Safety

Phase-Based Safety

2 of 3
This is further along than 68% of similar trials

Awards & Highlights

No Placebo Group
All patients enrolled in this trial will receive the new treatment.

Trial Design

3 Treatment Groups

Arm A
1 of 3
Arm B
1 of 3
MK-2140 (zilovertamab vedotin)
1 of 3

Experimental Treatment

140 Total Participants · 3 Treatment Groups

Primary Treatment: MK-2140 (zilovertamab vedotin) · No Placebo Group · Phase 2

Arm A
Biological
Experimental Group · 1 Intervention: MK-2140 (zilovertamab vedotin) · Intervention Types: Biological
Arm B
Biological
Experimental Group · 1 Intervention: MK-2140 (zilovertamab vedotin) · Intervention Types: Biological
MK-2140 (zilovertamab vedotin)
Biological
Experimental Group · 1 Intervention: MK-2140 (zilovertamab vedotin) · Intervention Types: Biological

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: up to approximately 50 months

Who is running the clinical trial?

Merck Sharp & Dohme Corp.Lead Sponsor
2,286 Previous Clinical Trials
4,578,255 Total Patients Enrolled
Merck Sharp & Dohme LLCLead Sponsor
3,733 Previous Clinical Trials
4,973,284 Total Patients Enrolled
Medical DirectorStudy DirectorMerck Sharp & Dohme LLC
2,668 Previous Clinical Trials
7,959,069 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 2 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You are expected to live for at least 3 months.
You have either already undergone CAR-T therapy and it did not work, or you are not eligible for CAR-T therapy for any reason.

Frequently Asked Questions

Has MK-2140 (zilovertamab vedotin) been formally sanctioned by the FDA?

"There is a limited amount of evidence suggesting the safety of MK-2140 (zilovertamab vedotin), thus it received an assessment score of 2. No data exists that confirms its efficacy." - Anonymous Online Contributor

Unverified Answer

How many institutes are participating in the experiment?

"The clinical trial is being conducted in multiple sites throughout the US, including AHN West Penn Hospital (Site 0212) in Pittsburgh, Pennsylvania; Saint Louis University Cancer Center ( Site 0209) in St. Louis, Missouri; and St. Joseph Hospital-The Center for Cancer Prevention and Treatment ( Site 0229) located in Orange , California amongst 16 other locations." - Anonymous Online Contributor

Unverified Answer

How many volunteers are participating in this research initiative?

"The sponsor of this trial, Merck Sharp & Dohme Corp., is in search of a total 100 patients who meet the criteria to partake. Patients can be seen at AHN West Penn Hospital ( Site 0212) in Pittsburgh, Pennsylvania and Saint Louis University Cancer Center (Site 0209) in Saint Louis, Missouri amongst other locations." - Anonymous Online Contributor

Unverified Answer

Is recruitment still ongoing for this investigation?

"Affirmative. The information hosted on clinicaltrials.gov states that this medical research is currently recruiting volunteers, and was first posted in the 8th of January 2022 with an update made at 24th November 2022. To be precise, 100 individuals are desired to join from 16 different trial sites." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.